Skip to main content

Advertisement

SpringerLink
Log in

Outcomes of a Phase II Study of Intraperitoneal Paclitaxel Plus Systemic Capecitabine and Oxaliplatin (XELOX) for Gastric Cancer with Peritoneal Metastases

  • Peritoneal Surface Malignancy
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Chia DKA, Sundar R, Kim G, et al. Outcomes of a phase II study of intraperitoneal paclitaxel plus systemic capecitabine and oxaliplatin (XELOX) for gastric cancer with peritoneal metastases. Ann Surg Oncol. 2022. https://doi.org/10.1245/s10434-022-11998-z (PMID: 36070113).

    Article  Google Scholar 

  2. Bonnot PE, Lintis A, Mercier F, et al. Prognosis of poorly cohesive gastric cancer after complete cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (CYTO-CHIP study). Br J Surg. 2021;108:1225–35. https://doi.org/10.1093/bjs/znab200 (PMID: 34498666).

    Article  CAS  Google Scholar 

  3. Rau, B., Lang, H., Königsrainer A, et al.: The effect of hyperthermic intraperitoneal chemotherapy (HIPEC) upon cytoreductive surgery (CRS) in gastric cancer (GC) with synchronous peritoneal metastasis (PM): a randomized multicentre phase III trial (GASTRIPEC-I-trial). Abstract 13760, Proffered paper session–gastrointestinal tumours, non-colorectal, ESMO Congress (2021)

  4. Yoshida K, Yasufuku I, Terashima M, et al. CONVO-GC-1 Study Group, Federation of Asian Clinical Oncology (FACO). International retrospective cohort study of conversion therapy for stage IV gastric cancer 1 (CONVO-GC-1). Ann Gastroenterol Surg. 2021;6:227–40. https://doi.org/10.1002/ags3.12515 (PMID: 35261948 PMCID: PMC8889854).

    Article  Google Scholar 

  5. Bonnot PE, Piessen G, Kepenekian V, et al. Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy for gastric cancer with peritoneal metastases (CYTO-CHIP study): a propensity score analysis. J Clin Oncol. 2019;37:2028–40. https://doi.org/10.1200/JCO.18.01688 (PMID: 31084544).

    Article  CAS  Google Scholar 

  6. Ishigami H, Fujiwara Y, Fukushima R, et al. Phase III trial comparing intraperitoneal and intravenous paclitaxel plus S-1 versus cisplatin plus S-1 in patients with gastric cancer with peritoneal metastasis: PHOENIX-GC trial. J Clin Oncol. 2018;36:1922–9. https://doi.org/10.1200/JCO.2018.77.8613 (PMID: 29746229).

    Article  CAS  Google Scholar 

  7. Eveno C, Jouvin I, Pocard M. PIPAC EstoK 01: pressurized intraperitoneal aerosol chemotherapy with cisplatin and doxorubicin (PIPAC C/D) in gastric peritoneal metastasis: a randomized and multicenter phase II study. Pleura Peritoneum. 2018;3:20180116. https://doi.org/10.1515/pp-2018-0116 (PMID: 30911659 PMCID: PMC6405009).

    Article  Google Scholar 

  8. Badgwell B, Ikoma N, Murphy MB, et al. A phase II trial of cytoreduction, gastrectomy, and hyperthermic intraperitoneal perfusion with chemotherapy for patients with gastric cancer and carcinomatosis or positive cytology. Ann Surg Oncol. 2021;28:258–64. https://doi.org/10.1245/s10434-020-08739-5 (PMID: 32556731).

    Article  Google Scholar 

  9. Basile D, Simionato F, Cappetta A, et al. State-of-the-art of monoclonal antibodies for the treatment of gastric cancer. Biologics. 2021;15:451–62. https://doi.org/10.2147/BTT.S290323 (PMID: 34764633 PMCID: PMC8572727).

    Article  Google Scholar 

  10. Gwee YX, Chia DKA, So J, et al. Integration of genomic biology into therapeutic strategies of gastric cancer peritoneal metastasis. J Clin Oncol. 2022;40:2830. https://doi.org/10.1200/JCO.21.02745 (PMID: 35649219 PMCID: PMC9390822).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgery, University Surgical Cluster, National University Health System, Singapore, Singapore

    Daryl K. A. Chia FRCS, Guowei Kim FRCS, Jia Jun Ang MRCS, Asim Shabbir FRCS & Jimmy B. Y. So MPH, FRCS

  2. Department of Haematology-Oncology, National University Cancer Institute National University Health System, Singapore, Singapore

    Raghav Sundar MRCP & Wei Peng Yong MRCP

  3. Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore

    Raghav Sundar MRCP, Guowei Kim FRCS, Asim Shabbir FRCS & Jimmy B. Y. So MPH, FRCS

  4. The N.1 Institute for Health, National University of Singapore, Singapore, Singapore

    Raghav Sundar MRCP

  5. Division of Surgical Oncology, National University Cancer Institute, National University Health System, Singapore, Singapore

    Guowei Kim FRCS, Asim Shabbir FRCS & Jimmy B. Y. So MPH, FRCS

  6. Cancer Science Institute of Singapore, National University of Singapore, Singapore, Singapore

    Wei Peng Yong MRCP

Authors
  1. Daryl K. A. Chia FRCS
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Raghav Sundar MRCP
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Guowei Kim FRCS
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jia Jun Ang MRCS
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Asim Shabbir FRCS
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Jimmy B. Y. So MPH, FRCS
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Wei Peng Yong MRCP
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jimmy B. Y. So MPH, FRCS.

Ethics declarations

Disclosure

This study was supported by the National Medical Research Council (NMRC) Translational and Clinical Flagship Programme (NMRC/TCR/009-NUHS/2013), NMRC Centre Grants (NMRC/CG/012/2013, NMRC/CG/M005/2017_NCIS) and NMRC Open Fund Large Collaborative Grant (OFLCG18May-9923). Dr Raghav Sundar is also supported by a NMRC Fellowships (NMRC/Fellowship/0059/2018 and NMRC/MOH/000627). Trial registry: NCT01739894.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Chia, D.K.A., Sundar, R., Kim, G. et al. Outcomes of a Phase II Study of Intraperitoneal Paclitaxel Plus Systemic Capecitabine and Oxaliplatin (XELOX) for Gastric Cancer with Peritoneal Metastases. Ann Surg Oncol 30, 1889–1890 (2023). https://doi.org/10.1245/s10434-022-12877-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-022-12877-3

Search

Navigation